Drug intelligence / Profile preview

DC-APCC

Development stage: Phase 2
Lead developer: Moffitt Cancer Center
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

**DC-APCC** is an investigational therapeutic cancer-vaccine regimen consisting of an allogeneic whole prostate carcinoma cell vaccine co-administered with ex vivo-generated autologous myeloid dendritic cells. The strategy is intended to enhance dendritic-cell presentation of prostate-tumor antigens and stimulate tumor-specific T-cell immune responses in patients with non-metastatic androgen-independent prostate cancer. It was evaluated by Mayo Clinic in the terminated Phase 2 study NCT00814892. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00814892))

Other names: allogeneic whole prostate carcinoma cell vaccine + autologous dendritic cellsDC-APCC

Beyond the preview

Go deeper on DC-APCC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DC-APCC.

Explore the full profile